Why the study?
Bleeding and thromboembolic events are common during vvECMO, but whether these complications are driven by the ECMO system itself, multiorgan failure, or both is unknown.
What is the prevalence of major bleeding and thromboembolic events in patients with isolated respiratory failure undergoing vvECMO?
What is the prevalence of major bleeding and thromboembolic events in patients with isolated respiratory failure undergoing vvECMO?
Major bleeding and thromboembolic events are highly prevalent in patients with isolated respiratory failure on vvECMO, occurring in 73% and 30% of patients respectively.
High bleeding (73%) and thromboembolic (30%) rates occur even in isolated respiratory failure on vvECMO; leaves open whether the circuit itself drives events independent of multiorgan failure.
Bleeding and thromboembolic events are common during veno-venous extracorporeal membrane oxygenation (vvECMO). It is unknown whether these complications are driven by the ECMO system itself, multiorgan-failure, or both. The aim of this study was to assess the prevalence of bleeding and thromboembolic events in patients with isolated respiratory failure. Patients with vvECMO were retrospectively included from March 2009 to October 2017. Exclusion included any organ failure other than respiratory. Major bleeding was defined as a decrease in hemoglobin ≥2 g/dl per 24 hours, the requirement for transfusion of ≥2 packed red blood cell concentrates per 24 hours, any retroperitoneal, pulmonary, central nervous system bleeding, or bleeding requiring surgery. Thromboembolic events were assessed by duplex sonography or CT scan. Of 601 patients, 123 patients with a mean age of 49 ± 15 years and a median Sepsis-related Organ Failure Assessment score of 8 (7-9) were eligible for the analysis. Major bleeding was observed in 73%; 35% of all bleedings occurred on the day of or after ECMO initiation. A more pronounced decrease of PaCO2 after ECMO initiation was seen in patients with intracranial bleeding (ICB) compared with those without. Thromboembolic events were noted in 30%. The levels of activated prothrombin time, fibrinogen, platelet count, or D-dimers affected neither bleeding nor the prevalence of thromboembolic events.
No takes yet. Share an insight, caveat, or question.
Baumgartner et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: